| Bioactivity | UK-1745 is a cardiotonic agent with vasodilatory and antiarrhythmic properties that increases intracardiac cAMP levels by inhibiting phosphodiesterase III, thereby enhancing myocardial contractility. UK-1745 also has β-adrenergic receptor blocking activity, which helps reduce cardiac oxygen consumption and avoid calcium overload. UK-1745 can be used in the study of congestive heart failure[1][2]. |
| CAS | 170684-14-7 |
| Formula | C16H23ClN2O2 |
| Molar Mass | 310.82 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sawada, et al. "Pharmacological Characterization of Effects of UK-1745, a Novel Cardiotonic Agent withβ-Adrenoceptor-blocking Action, in Aequorin-loaded Canine Right Ventricular Muscle." Journal of molecular and cellular cardiology 31.5 (1999): 1047-1062. [2]. Uchida, et al. "Cardiovascular effects of (2RS, 3SR)-2-aminomethyl-2, 3, 7, 8-tetrahydro-2, 3, 5, 8, 8-pentamethyl-6H-furo-[2, 3-e] indol-7-one hydrochloride (UK-1745), a novel cardiotonic agent with vasodilatory and antiarrhythmic properties." Arzneimittel-forschung 48.3 (1998): 219-231. |
UK-1745
CAS: 170684-14-7 F: C16H23ClN2O2 W: 310.82
UK-1745 is a cardiotonic agent with vasodilatory and antiarrhythmic properties that increases intracardiac cAMP levels b
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.